Looking beyond tremor to the emotional weight of Parkinson's
When people picture Parkinson's disease, they often think first of tremor, stiffness, or slowed movement. Yet for many living with the condition, some of the heaviest burdens are invisible. Depression and anxiety are among the most common and challenging aspects of Parkinson's, and they can appear even before motor symptoms. These non-motor symptoms can have a profound impact on daily functioning, relationships, and quality of life.
Existing treatments for mood symptoms in Parkinson's do not work equally well for everyone, leaving a meaningful gap in care. It is this gap that has drawn researchers, and a growing number of patients, to take a serious scientific look at psilocybin, the naturally occurring psychedelic compound found in certain mushrooms.
A First Look From the Clinic
In 2025, researchers at the University of California, San Francisco, reported results from an early clinical trial of psilocybin therapy in people with Parkinson's disease. In this small, open-label pilot study, 12 participants with mild to moderate Parkinson's who also experienced depression or anxiety received two supervised doses of psilocybin, 10 mg followed by 25 mg, paired with psychotherapy and structured support.¹
An important early finding concerned safety and feasibility within the carefully controlled study setting. No serious adverse events were reported, and no medical intervention was needed to manage the effects of the psilocybin sessions. However, 10 of the 12 participants experienced treatment-emergent adverse events, most commonly temporary anxiety, nausea, and increased blood pressure.¹
Researchers also observed encouraging improvements in depression and anxiety scores that persisted through the final assessment three months after treatment. Improvements were reported in certain motor and cognitive measures as well, although these exploratory findings do not establish that psilocybin improves Parkinson's motor symptoms or changes the underlying disease.¹
Because this was a small, open-label study without a placebo group, the results must be interpreted cautiously. Participants knew they were receiving psilocybin, and the treatment included psychotherapy and structured support, making it difficult to separate the effects of each component. These findings are a starting point, not a conclusion, but they provide a reason to pursue larger, more rigorous studies.
Why Psilocybin, and Why Now?
Interest in psilocybin has grown across medicine over the past decade, with research institutions studying its potential for treatment-resistant depression, anxiety, and other mental health conditions.
The U.S. Food and Drug Administration has granted breakthrough therapy designation to specific psilocybin-assisted treatment programs for depression, including programs investigating treatment-resistant depression and major depressive disorder. This designation recognizes promising preliminary clinical evidence and is intended to facilitate further development and review. It does not mean psilocybin has received FDA approval or that it has been demonstrated to treat Parkinson's disease.²
For the Parkinson's community specifically, more rigorous research is now underway. UCSF is conducting a randomized Phase 2 trial investigating psilocybin-assisted therapy for depression in people with Parkinson's, with a planned enrollment of 60 participants. Yale is also participating in controlled research examining this question.³
These studies will be essential to understanding whether the early improvements can be reproduced, how long any benefits may last, and which patients might be most likely to benefit.
What This Means for Patients and Families
It is essential to be clear: psilocybin is not a cure for Parkinson's, and it remains a controlled substance under federal law. Encouraging early research does not establish that it is safe or effective for independent use.
Psilocybin can affect blood pressure, produce significant psychological effects, and pose risks for people with certain medical or psychiatric conditions or medication regimens. Careful screening, appropriate supervision, and structured support are important components of the clinical research being conducted.
For people living with Parkinson's, the importance of this research extends beyond depression and anxiety scores. Emotional well-being influences relationships, motivation, independence, and the ability to engage in everyday life. Many patients describe changes in how they feel, think, and connect with others that can be just as difficult to navigate as their physical symptoms.
Research should also consider the outcomes patients themselves identify as meaningful. Improvements in quality of life, emotional resilience, daily functioning, and the ability to participate more fully in family and community life may be especially important when evaluating emerging approaches.
What this early research offers is reason for careful optimism. It also reinforces something the Parkinson's community has long understood: the emotional dimensions of this disease deserve meaningful attention alongside its physical symptoms.
The TPPF Perspective
At The Parkinson's Project Foundation, we believe people living with Parkinson's deserve honest, accessible information about emerging therapies, even when the science is still developing. That includes approaches that have historically received less attention, such as psychedelic-assisted therapy.
The early research on psilocybin raises important questions about how we understand and address the emotional and psychological challenges of Parkinson's. Depression, anxiety, apathy, and changes in emotional well-being can significantly affect quality of life, yet these experiences are not always given the same attention as motor symptoms.
We believe education, prevention, early intervention, and whole-person health deserve greater emphasis in Parkinson's care. We also recognize that promising findings require careful investigation before conclusions can be drawn about safety, effectiveness, or long-term benefits.
Patient voices are essential to that process. Lived experiences can help identify unmet needs, raise meaningful research questions, and highlight outcomes that traditional clinical measurements may overlook. Those experiences deserve to be heard and investigated without being mistaken for proof of effectiveness.
Our role is not to promote any single therapy or direct individual treatment decisions. It is to encourage informed choice, support responsible research, reduce stigma, and advocate for greater access to trustworthy information and appropriate care.
People living with Parkinson's deserve to understand what is being explored, what remains uncertain, and how they can participate in decisions about their own health.
References
Bradley ER, Sakai K, Fernandes-Osterhold G, et al. "Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial." Neuropsychopharmacology. 2025;50:1200–1209. Published April 9, 2025. https://doi.org/10.1038/s41386-025-02097-0
U.S. Food and Drug Administration. "Fact Sheet: Breakthrough Therapies." https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-breakthrough-therapies
U.S. Food and Drug Administration. "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments." 2026. Includes background on breakthrough therapy designations granted to psilocybin development programs. https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=Considerations+for+Potential+Future+Therapeutic+Use+of+Psychedelic+DrugsClinicalTrials.gov. "The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease." NCT06455293. https://clinicaltrials.gov/study/NCT06455293
University of California, San Francisco. "Psilocybin Therapy for Depression in Parkinson's Disease." https://clinicaltrials.ucsf.edu/trial/NCT06455293
Yale School of Medicine. "The PSI-PD Study: Psilocybin for Depression in Parkinson's Disease." https://medicine.yale.edu/psychiatry/research/clinics-and-programs/depression/research/psi-pd-study/
Note: This article is intended for educational purposes only and does not constitute medical or legal advice. Psilocybin remains a controlled substance under federal law, with limited exceptions and varying state-regulated frameworks. It has not been approved by the FDA to treat Parkinson's disease. Individuals considering participation in research or exploring treatment options should consult qualified healthcare professionals and review applicable laws.
